Italian injection

The companies' revenues last year reached EUR 15 (zł.59) million while their profits amounted to EUR 1 (zł.3.9) million. The two companies have been valued at EUR 17 (zl.67) million.

Entering the Italian market is another step forward in Bioton's global strategy.

"The Italian market is the second-largest pharmaceutical market in Europe. It will be easier to get there if we use the existing profitable companies with their distribution channels," says Adam Wilczęga, president of Bioton. "We aim to introduce our present and future biotechnological products in the Western European markets. We know it's a long and demanding project, but we are making the first step towards it right now," he adds.

In May, the general meeting of shareholders approved issuing 1.7 billion additional shares, which will co-finance Bioton's current investments.